Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best stocks with the highest upside potential. Guggenheim assumed coverage on Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) with a “Buy” rating and a price target of $8.00, implying a surge of 146.5% from the current price. The analysts have high expectations for the company’s silevertinib Phase 2 data due in the second half of 2025.

Guggenheim believes silevertinib’s preclinical profile, which is designed for broad-spectrum mutation selectivity over wild-type EGFR, positions Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) well to meet the set 50% objective response rate (ORR) and 10-month median progression-free survival (mPFS) metrics. Adding to this are strong second-line response rates after osimertinib treatment that could attract strategic partnerships in the future.

If we consider the company’s year-to-date return, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) has surpassed the market by nearly 40%. For what it’s worth, now is the time to take a position in the stock because when the stock rallies, it could rally hard.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), headquartered in Cambridge, Massachusetts, is a 2014-formed clinical-stage oncology company that discovers and develops MasterKey therapies for people living with genetically defined tumors.

While we acknowledge the potential of BDTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.